Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Safety and Preliminary Efficacy of ANS-6637 to Reduce Drug Craving and Harm in People With Opioid Use Disorder (SEARCH)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04169360
Recruitment Status : Not yet recruiting
First Posted : November 19, 2019
Last Update Posted : November 21, 2019
Sponsor:
Information provided by (Responsible Party):
Sarah Kattakuzhy, University of Maryland, Baltimore

Brief Summary:
This is a double blind, placebo controlled, randomized trial to evaluate the safety and preliminary efficacy of ANS-6637 in adults with opioid use disorder with and without opioid agonist therapy. Patients will be randomized to two arms: (1) ANS-6637 for three months vs (2) Placebo for three months. Subjects will subsequently be followed for an additional one month post treatment.

Condition or disease Intervention/treatment Phase
Opioid-use Disorder Drug: ANS-6637 Drug: Placebo oral tablet Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 82 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Safety and Preliminary Efficacy of ANS-6637 to Reduce Drug Craving and Harm in People With Opioid Use Disorder
Estimated Study Start Date : January 2020
Estimated Primary Completion Date : May 2021
Estimated Study Completion Date : May 2021

Arm Intervention/treatment
Experimental: ANS-6637
ANS-6637 600mg once daily for 12 weeks
Drug: ANS-6637
White, oblong 300 mg tablet

Placebo Comparator: Placebo arm
Placebo 600 mg once daily for 12 weeks
Drug: Placebo oral tablet
White, oblong 300 mg tablet




Primary Outcome Measures :
  1. Number of Grade 3-4 events, Grade 2 Significant event [ Time Frame: 16 weeks ]
    The number of Grade 3-4 adverse events, as defined by the Division of AIDS (DAIDS) Toxicity Table Version 2.1, July, 2017 as well as the number of Grade 2 events requiring medication interruption or deemed clinically significant by a study investigator


Secondary Outcome Measures :
  1. Urine Drug Screen [ Time Frame: 16 weeks ]
    Percentage opioid free period by urine drug screen

  2. Opioid Craving [ Time Frame: 16 weeks ]
    Opioid craving will be assessed using the Opioid Craving scale questionnaire. The questionnaire consists of three questions and each of these questions has a minimum value of 0 and a maximum value 10. A score of 0 on each question is the best outcome; a score of 10 on each question is the worst outcome.

  3. Opioid Agonist Therapy (OAT) concentration [ Time Frame: 16 weeks ]
    Serum concentration of buprenorphine or methadone

  4. Self reported description of drug use (Self-reported frequency/quantity/mode of opioid use, self-reported use of other drugs, overdose and overdose death) [ Time Frame: 16 weeks ]
    Self-reported frequency/quantity/mode of opioid use as well as self-reported use of other drugs will be gathered using the Drug Use Survey. Subjects will indicate frequency of opioid use by documenting the number of times they used an opioid during a given day. The quantity of opioids used will be determined by the dollar amount of opioids the subject reports they have consumed during that day. Subjects will also report mode of opioid use by indicating whether they are using opioids via injection, skin popping, snorting or oral. The Drug Use Survey will also ask subjects to report incidence of use of non-opioid substances. Incidence of overdose will be captured with the Naloxone questionnaire which asks, "since you last visit, have you experienced an overdose?". Incidence of overdose death will measured by the number of medical examiner confirmed deaths of study participants with cause of death listed as "overdose related to an opioid".


Other Outcome Measures:
  1. Change in Darke HIV Risk Taking Behavior Survey Score [ Time Frame: 16 weeks ]
    The Darke HIV Risk Taking Behavior Questionnaire will be administered to assess subject's self-reported risk taking behaviors. Total scores on the test range from 0 to 55, with higher scores indicating a greater degree of risk-taking behavior.

  2. Change in HIV Test Result [ Time Frame: 16 weeks ]
    An HIV test (fourth generation antigen/antibody test) will be administered and the results are reported as either positive or negative.

  3. Change in Hepatitis C (HCV) RNA result [ Time Frame: 16 weeks ]
    A Hepatitis C (HCV) RNA test will be administered. This test measures the quantity of detectable RNA which is measured in IU/ml.

  4. Change in appetite [ Time Frame: 16 weeks ]
    Self reported changes in appetite will be captured by the Adverse Event Survey. The survey will ask, "since your last visit, have you had an increase in your appetite or a decrease in your appetite?".



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Must have the ability to understand and must personally sign a written informed consent form, which must be obtained prior to initiation of study procedures.
  • Must be between 18 and 65 years of age, inclusive.
  • Must have the diagnosis of opioid use disorder by DSM (Diagnostic and Statistical Manual of Mental Disorders) V criteria of at least mild severity
  • Must have a total score of 9 or greater (out of a total of 30) on the Opioid Craving Scale at screening
  • If on opioid agonist therapy, must be on Opioid Agonist Therapy (OAT) medication for a minimum of six months prior to screening.
  • If on medication for depression or anxiety, must be on a stable dose for a minimum of two months prior to screening.
  • Must be able to take oral medication and be willing to adhere to the medication regimen
  • Must agree to utilize the "AI Cure" platform, either on their personal phone or on a supplied device, for both daily video adherence monitoring as well as daily questionnaires for the entire study duration.
  • Male subjects must refrain from sperm donation throughout the study period, and continuing for at least 90 days following the last dose of study drug.
  • Subjects must refrain from blood donation throughout the study period, and continuing for at least 30 days following the last dose of study drug.
  • Must be willing to comply with contraception guidelines: The fetal risks associated with ANS-6637 are not known, but pre-clinical animal data demonstrate some risk. Subjects must agree not to become pregnant or impregnate a female. Females of childbearing potential must have a pregnancy test at screening and baseline (Day 0). If pregnancy occurs or is suspected to occur, study staff must be notified immediately. For the duration of the study, subjects or female partners of childbearing potential must use one of the following, unless she is surgically sterile, post-menopausal, or partner is surgically sterile: oral contraceptives (OCP), contraceptive sponge, patch double barrier (diaphragm + spermicide or condom + spermicide), intrauterine device (IUD), etonogestrel implant, injection, hormonal vaginal contraceptive ring or complete abstinence
  • Must be willing and able to comply with all study requirements and plan to attend all clinic visits.

Exclusion Criteria:

A subject will be ineligible for this study if 1 or more of the following criteria are met:

  • Clinically significant AND grade 2 or higher abnormal laboratory values at screening, as determined by principal investigator
  • Aspartate transaminase (AST) or Alanine transaminase (ALT) > 2.5 x upper limit of normal or total bilirubin > 1.6 x the upper limit of normal
  • Creatinine clearance < 60 mL/min/1.73m2 by Chronic kidney disease (CKD)-Epidemiology Collaboration (EPI) Score.
  • Personal or family history of Parkinson's Disease
  • Diagnosed major depression AND with current self-reported depression episode
  • Diagnosed generalized anxiety disorder AND with current self-reported uncontrolled anxiety
  • Current self-reported suicidal ideation
  • Diagnosed liver disease, including untreated chronic Hepatitis C (defined as detectable Hepatitis C RNA), Hepatitis B (defined as positive HBsAg), and/or cirrhosis (defined as Fibrosis (FIB)-4 > 3.25 AND confirmed by Fibroscan or Fibrosure)
  • Diagnosed Human Immunodeficiency Virus (HIV) AND detectable viral load > 40 copies/mL
  • Diagnosed moderate or serious dementia Taking any of the following medications in the last 6 months: dopamine agonist, dopamine antagonist, anti-psychotic, anti-convulsant (except for benzodiazepines and gabapentin) or barbiturate
  • Inability to obtain venous access for sample collection.
  • Had a prior history of any severe adverse reactions to ethanol [e.g., flushing (noticeable redness of the neck or throat) and/or increased heart rate (subject reports sensation of increased heart rate or palpitations) after drinking alcohol].
  • Known hypersensitivity to formulation excipients: microcrystalline cellulose, croscarmellose sodium, magnesium stearate, polyvinyl alcohol, titanium dioxide, polyethylene glycol, and talc.
  • Have previously participated in an investigational trial involving administration of any investigational compound within 30 days prior to screening
  • Have any unresolved legal issues that could jeopardize continuation or completion of the study, at the discretion of the principal investigator
  • Have any serious or active medical, surgical, or psychiatric conditions which, in the opinion of the Investigator, would interfere with subject treatment, assessment, or compliance with the protocol.
  • Are unable to comply with study requirements

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04169360


Contacts
Layout table for location contacts
Contact: Onyinyechi Ogbumbadiugha, MPH 4436354943 oogbumbadiugha@ihv.umaryland.edu
Contact: Rachel Silk, RN, MPH 3013267652 rsilk@ihv.umaryland.edu

Sponsors and Collaborators
University of Maryland, Baltimore
Investigators
Layout table for investigator information
Principal Investigator: Sarah Kattakuzhy, MD Institute of Human Virology at the University of Maryland

Layout table for additonal information
Responsible Party: Sarah Kattakuzhy, Principal Investigator, University of Maryland, Baltimore
ClinicalTrials.gov Identifier: NCT04169360     History of Changes
Other Study ID Numbers: HP-00088649
First Posted: November 19, 2019    Key Record Dates
Last Update Posted: November 21, 2019
Last Verified: November 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: The investigator will share de-identified data with approved outside collaborators under appropriate agreements, at the time of publication or shortly thereafter.
Supporting Materials: Study Protocol
Statistical Analysis Plan (SAP)
Analytic Code
Time Frame: Data will be available at the time of publication or shortly thereafter, and will be kept indefinitely.

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Substance-Related Disorders
Chemically-Induced Disorders
Mental Disorders